Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome [0.03%]
透析生物反应器能够实现高密度、无血清诱导牙髓源性间充质干细胞增殖并改善其分泌组分
Fuad Gandhi Torizal,Yudha Tirtadani,Alessandro Volta Gunady et al.
Fuad Gandhi Torizal et al.
Dental pulp-derived mesenchymal stromal cells (DPSCs) offer a potential source for both autologous cell-based and cell-free therapies aimed at treating a wide range of diseases. However, current culture practices predominantly rely on serum...
Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors? [0.03%]
超越突触：在制造用于脑肿瘤的CAR-T细胞时是否应该预期神经递质信号传递？
Mostafa Seblani,Serge Yaacoub,Patrick J Hanley et al.
Mostafa Seblani et al.
Brain tumors remain among the most challenging solid tumors to treat. Progress in Chimeric Antigen Receptor T (CAR-T) cell-based therapy in patients with hematological malignancies has offered an increasing interest in using this approach i...
Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy [0.03%]
重度镰状细胞病的根治性治疗：同种异体造血干细胞移植还是基因治疗
Mary Eapen,David A Williams
Mary Eapen
Sickle cell disease (SCD) is characterized by chronic hemolysis, ischemia-reperfusion injury, and progressive end organ damage. Although survival for children with SCD in the United States (US) is excellent the life expectancy for adults is...
Noriko Shimasaki
Noriko Shimasaki
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, achieving durable remission in patients who are refractory to conventional therapies. However, the limited persistence of infused C...
Megha Thakkar,Patrick J Hanley,Alexey Bersenev et al.
Megha Thakkar et al.
The development and application of chimeric antigen receptor (CAR) T-cell therapies have changed the treatment landscape of hematologic malignancies. While there are currently FDA approved products for their use in relapsed or refractory B-...
Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field [0.03%]
新冠肺炎疫情下的骨髓间充质基质细胞治疗：一项学术界I/ II期、双盲、随机和安慰剂对照临床试验的结果及对未来研究的反思
Antoni Torres,Judith Marin-Corral,Ramon Adalia-Bartolome et al.
Antoni Torres et al.
Background: During the COVID-19 pandemic, Mesenchymal Stromal Cells (MSCs) were rapidly proposed as a therapeutic option for Acute Respiratory Distress Syndrome (ARDS) based on their immunomodulatory properties. We report...
Rethinking CAR-T manufacturing paradigms: terminology, operational considerations, and economic trade-offs [0.03%]
从术语、运营考量和经济权衡三个方面重新思考CAR-T制造范式
Chase McCann,Jacob Matriccino,Mark Lowdell et al.
Chase McCann et al.
Background: Manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies has matured significantly over the past decade, with improvements in automation, closed-system processing, and digital platforms enhancing re...
Characterizing the effects of MSC lipid remodeling via sphingomyelinase licensing through morphological, metabolic, and secretome profiling [0.03%]
通过形态学、代谢和分泌组谱分析MSC脂质重塑的特征及其通过鞘磷脂酶许可的作用效应
S&#x;Dravious A DeVeaux,Daniel C Shah,Kejie Rui et al.
S&#x;Dravious A DeVeaux et al.
Mesenchymal stromal cells (MSCs) are widely studied for their immunomodulatory and tissue reparative capabilities. However, clinical translation has been hampered by inconsistent efficacy and limited standardization in manufacturing. While ...
A novel method for efficient murine regulatory T-cell expansion and retroviral transduction [0.03%]
一种有效的小鼠调节性T细胞增殖和逆转染的新型方法研究
Cameron McDonald-Hyman,Pooja Shree Marri Baskar,Yiyun Peng et al.
Cameron McDonald-Hyman et al.
Background aims: Regulatory T-cell (Treg) infusions are an emerging therapy for the prevention or treatment of autoimmune, alloimmune and inflammatory disorders. Tregs that are modified to express a chimeric antigen recep...
Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors [0.03%]
儿科患者自身T细胞血浆置换在血液系统恶性肿瘤、实体瘤及脑瘤中的成功应用
Devin Murphy,Yu Bi,Aysha Patel et al.
Devin Murphy et al.
Background: Chimeric antigen receptor (CAR) T cell therapy is being used to target a range of pediatric cancers. Starting materials are critical for successful CAR T cell manufacturing, most often obtained via autologous ...